14-day Premium Trial Subscription Sign Up For FreeGet Free

Catabasis Pharmaceuticals Stock Forecast NASDAQ:CATB

Price Target and Analyst Ratings

Most Recent Rating

On September 02, 2021 "Wedbush" gave "$16.00" rating for CATB. The price target was changed from $9.41 to 5.6%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-02 $16.00 Initiated by Wedbush $10.06 $9.41→5.6%
2021-08-25 $13.00 Upgraded by HC Wainwright $9.26 $8.72→0.9%
2021-05-18 Buy Initiated by LADENBURG THALM/SH SH $1.87 $6.00
2021-05-12 Buy Initiated by LADENBURG THALM/SH SH $1.77 $6.00
2021-05-12 Buy Initiated by LADENBURG THALM/SH SH $1.77
2021-03-17 Market Perform - Outperform Upgraded by Oppenheimer $3.58 $5.00
2021-03-11 Market Perform - Outperform Upgraded by Oppenheimer $3.46 $5.00
2021-02-01 Hold Reiterated by HC Wainwright $3.64
2020-11-02 Outperform - Neutral Downgraded by Wedbush $1.36
2020-10-27 Outperform - Market Perform Downgraded by Oppenheimer $1.56
2020-10-27 Buy - Neutral Downgraded by HC Wainwright $1.56
2020-10-01 Buy Initiated by HC Wainwright $6.30 $24.00 → $24.00
2020-09-15 Buy Reiterated by Oppenheimer $6.53 $60.00
2020-08-20 Buy Reiterated by Wedbush $6.73 $15.00

CATB Stock Trend

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 305.52% during the next 3 months and, with a 90% probability hold a price between $16.97 and $47.87 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-22 $4.33 $8.14 $11.95
2021-09-23 $4.47 $8.28 $12.09
2021-09-24 $4.61 $8.42 $12.23
2021-09-27 $4.75 $8.56 $12.37
2021-09-28 $4.89 $8.70 $12.51
2021-09-29 $5.03 $8.84 $12.65
2021-09-30 $5.17 $8.98 $12.79
2021-10-01 $5.31 $9.12 $12.93
2021-10-04 $5.46 $9.27 $13.08
2021-10-05 $5.60 $9.41 $13.22
2021-10-06 $5.74 $9.55 $13.36
2021-10-07 $5.88 $9.69 $13.50
2021-10-08 $6.02 $9.83 $13.64
2021-10-11 $6.16 $9.97 $13.78
2021-10-12 $6.30 $10.11 $13.92
2021-10-13 $6.44 $10.25 $14.06
2021-10-14 $6.58 $10.40 $14.21
2021-10-15 $6.73 $10.54 $14.35
2021-10-18 $6.87 $10.68 $14.49
2021-10-19 $7.01 $10.82 $14.63
2021-10-20 $7.15 $10.96 $14.77
2021-10-21 $7.29 $11.10 $14.91
2021-10-22 $7.43 $11.24 $15.05
2021-10-25 $7.57 $11.38 $15.19
2021-10-26 $7.71 $11.52 $15.33
2021-10-27 $7.86 $11.67 $15.48
2021-10-28 $8.00 $11.81 $15.62
2021-10-29 $8.14 $11.95 $15.76
2021-11-01 $8.28 $12.09 $15.90
2021-11-02 $8.42 $12.23 $16.04

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT